The studies presented here examine RICTOR/mTORC2 signaling in HNSCC specifically, where PI3K inhibition is one of the leading targeted therapies currently under investigation (Lui et al., 2013; Rodon et al., 2013). The gene discussed is RICTOR; the disease is head and neck squamous cell carcinoma.